IOLCP IOL Chemicals and Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
IOL Chemicals reported a resilient Q3 FY26 with strong revenue and EBITDA growth, driven by diversified business model and disciplined execution. Non-ibuprofen molecules and the chemicals segment showed robust performance, contributing to margin expansion. Despite global headwinds and higher fuel costs impacting margin targets, the company declared an interim dividend and remains focused on strategic growth initiatives, including minoxidil commercialization and R&D pipeline development.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.9%, net profit up 0.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 526 | 523 | 528 | 552 | 568 +8% | 580 +11% |
| EBITDA | 42 | 47 | 63 | 62 | 57 +36% | 57 +21% |
| Net profit | 19 | 21 | 32 | 34 | 30 +58% | 21 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
